Pfizer breast cancer treatment granted FDA priority review status
October 13, 2014 at 08:55 AM EDT
Pfizer’s experimental breast-cancer treatment, palbociclib, has been granted priority review status by the FDA, which expedites the review time from 10 months to a goal of six months.
